<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348607</url>
  </required_header>
  <id_info>
    <org_study_id>SCUSF 0803</org_study_id>
    <secondary_id>SCUSF-0803</secondary_id>
    <secondary_id>5U10CA081920-11</secondary_id>
    <nct_id>NCT01348607</nct_id>
  </id_info>
  <brief_title>Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy</brief_title>
  <official_title>A Randomized, Phase II Placebo-controlled Study of the Use of Extended-release Methylphenidate or Modafinil for the Treatment of Excessive Daytime Sleepiness in Children Following Cancer Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Methylphenidate hydrochloride or modafinil may help reduce daytime sleepiness and&#xD;
      improve the quality of life of patients with excessive daytime sleepiness after cancer&#xD;
      therapy. It is not yet known whether methylphenidate hydrochloride or modafinil are more&#xD;
      effective than a placebo in reducing daytime sleepiness in these patients.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying methylphenidate hydrochloride or&#xD;
      modafinil to see how well they work compared with a placebo in treating young patients with&#xD;
      excessive daytime sleepiness after cancer therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the efficacy of methylphenidate hydrochloride and modafinil to placebo in&#xD;
           pediatric patients with excessive daytime sleepiness following cancer therapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the efficacy of half dose methylphenidate hydrochloride and modafinil to placebo&#xD;
           in these patients.&#xD;
&#xD;
        -  Assess the effects of these regimens on daytime sleepiness as measured by the Pediatric&#xD;
           Daytime Sleepiness Scale or the Cleveland Adolescent Sleepiness Questionnaire.&#xD;
&#xD;
        -  Assess the effects of somnolence symptoms on fatigue as measured by the PedsQL&#xD;
           Multidimensional Fatigue Scale.&#xD;
&#xD;
        -  Assess the effects of somnolence symptoms on the quality of life as measured by the&#xD;
           PedsQL Quality of Life Inventory 4.0.&#xD;
&#xD;
        -  Determine the incidence of side effects associated with these regimens.&#xD;
&#xD;
        -  Determine the prevalence of sleep complaints as measured by the Pediatric Sleep&#xD;
           Questionnaire. (Exploratory)&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to age (8-10 years vs&#xD;
      11-12 years vs 13-17 years vs 18-25 years). Patients are randomized to 1 of 3 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral methylphenidate hydrochloride extended-release once daily&#xD;
           for 7-42 days in the absence of unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive oral modafinil once daily for 7-42 days in the absence of&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Arm III: Patients receive oral placebo once daily for 7-42 days in the absence of&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Patients or their parents complete age-specific sleep and quality-of-life questionnaires at&#xD;
      baseline and after completion of treatment. Patients or their parents complete daily sleep&#xD;
      diaries during the study to collect information about the date, type of day (school, weekend,&#xD;
      or vacation), hours of sleep, anytime the actigraph was removed during the day, time the&#xD;
      child went to bed, and time the child got out of bed in the morning. Patients are also&#xD;
      instructed to wear an actigraph on their non-dominant wrist for 1 week before starting&#xD;
      treatment and during the first and last week of treatment (3 weeks total) to assess&#xD;
      sleep-wake patterns.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study only randomized 1 subject and was determined not feasible by DSMB&#xD;
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Daytime Napping Minutes in a Week</measure>
    <time_frame>29 days</time_frame>
    <description>Outcome measure was the total of daytime napping minutes in a week as assessed by participant sleep diaries</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>29 days</time_frame>
    <description>Adverse events assessed at all subject visits by interviews with the subject and the subject's parent/ primary caregiver.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Central Nervous System Tumor, Pediatric</condition>
  <condition>Fatigue</condition>
  <condition>Specific Disorders of Sleep</condition>
  <arm_group>
    <arm_group_label>Arm I - methylphenidate hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II -modafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylphenidate hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I - methylphenidate hydrochloride</arm_group_label>
    <other_name>methylphenidate HCl</other_name>
    <other_name>Concerta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>modafinil</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II -modafinil</arm_group_label>
    <other_name>Provigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm III placebo</arm_group_label>
    <other_name>potato starch placebo</other_name>
    <other_name>placebo capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Patient and family must agree to return to the clinic up to 8 times within 2 months&#xD;
&#xD;
          -  Children â‰¥ 8 and &lt;18 years of age at the time of study entry who were previously&#xD;
             treated for:&#xD;
&#xD;
          -  a hypothalamic tumor&#xD;
&#xD;
          -  mid-line brain tumor&#xD;
&#xD;
          -  a tumor involving one or both thalami&#xD;
&#xD;
          -  craniopharyngioma&#xD;
&#xD;
          -  diagnosis of hydrocephalus secondary to a brain tumor or treatment of a brain tumor&#xD;
             that required placement of a permanent shunt.&#xD;
&#xD;
          -  Off cancer treatment for at least six months&#xD;
&#xD;
          -  Proficient in English&#xD;
&#xD;
          -  Able to swallow capsules&#xD;
&#xD;
          -  Experiencing symptoms of excessive daytime sleepiness (EDS) for at least three months&#xD;
             prior to study entry that is not a result of inadequate sleep hygiene or other known&#xD;
             medical disorder.&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Patients treated with doxorubicin or high dose cyclophosphamide&#xD;
&#xD;
          -  History of a clinically significant drug sensitivity to methylphenidate, modafinil,&#xD;
             armodafinil or any of their components&#xD;
&#xD;
          -  Known cardiac disorders including arrhythmias, hypertension requiring treatment or&#xD;
             structural heart disease&#xD;
&#xD;
          -  Have taken methylphenidate or modafinil within the last 14 days&#xD;
&#xD;
          -  Current/concurrent use of antihistamines, benzodiazepine, anticonvulsants or alcohol&#xD;
&#xD;
          -  Clinical diagnosis of major depression, subclinical depression, or anxiety disorder&#xD;
&#xD;
          -  History of psychosis or mania&#xD;
&#xD;
          -  Patients with suicidal ideation&#xD;
&#xD;
          -  Diagnosis with anemia, untreated hypothyroidism, mononucleosis or narcolepsy&#xD;
&#xD;
          -  History of substance abuse&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  A total dietary intake of more than 500 mg of caffeine per day (e.g., approximately&#xD;
             ten 330 mL cans of soft drinks, five cups of coffee or tea, or 750 g chocolate per&#xD;
             day).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald Rosen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospitals and Clinics of Minnesota - St. Paul</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom Geller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Louis University</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>May 4, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <results_first_submitted>July 5, 2013</results_first_submitted>
  <results_first_submitted_qc>September 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2013</results_first_posted>
  <last_update_submitted>January 23, 2014</last_update_submitted>
  <last_update_submitted_qc>January 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psychosocial effects of cancer and its treatment</keyword>
  <keyword>sleep disorders</keyword>
  <keyword>fatigue</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Disorders of Excessive Somnolence</mesh_term>
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Sleepiness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I - Methylphenidate Hydrochloride</title>
          <description>Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Arm II -Modafinil</title>
          <description>Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="P3">
          <title>Arm III Placebo</title>
          <description>Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I - Methylphenidate Hydrochloride</title>
          <description>Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Arm II -Modafinil</title>
          <description>Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Arm III Placebo</title>
          <description>Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.9"/>
                    <measurement group_id="B4" value="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Daytime Napping Minutes in a Week</title>
        <description>Outcome measure was the total of daytime napping minutes in a week as assessed by participant sleep diaries</description>
        <time_frame>29 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Methylphenidate Hydrochloride</title>
            <description>Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm II -Modafinil</title>
            <description>Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Arm III Placebo</title>
            <description>Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Daytime Napping Minutes in a Week</title>
          <description>Outcome measure was the total of daytime napping minutes in a week as assessed by participant sleep diaries</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Adverse events assessed at all subject visits by interviews with the subject and the subject's parent/ primary caregiver.</description>
        <time_frame>29 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Methylphenidate Hydrochloride</title>
            <description>Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm II -Modafinil</title>
            <description>Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Arm III Placebo</title>
            <description>Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Adverse events assessed at all subject visits by interviews with the subject and the subject's parent/ primary caregiver.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <desc>Complete and frequent monitoring for adverse events (AEs) were incorporated using the Systematic Assessment for Treatment Emergent Effects (SAFTEE),developed by the National Institute of Mental Health. AEs will also be assessed by weekly physical exam, review of patient/caregiver daily sleep and medicine logs and patient/caregiver interview.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I - Methylphenidate Hydrochloride</title>
          <description>Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Arm II -Modafinil</title>
          <description>Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="E3">
          <title>Arm III Placebo</title>
          <description>Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was closed prior to completion due to a lack of feasibility and low accrual by the Data Monitoring and Safety Board (DSMB).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Cristina Burroughs, Clinical Research Administrator</name_or_title>
      <organization>SunCoast CCOP Research Base</organization>
      <phone>(813) 396-9237</phone>
      <email>Cristina.Burroughs@epi.usf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

